Cargando…
High levels of fecal calprotectin and C-reactive protein in patients with colitis
Inflammatory bowel disease (IBD) with a poor prognosis may be due to persistent colitis. According to the latest guidelines, monitoring has become a part of the treatment process for colitis. Adequate monitoring of the patient's condition is necessary to determine the course of the disease to p...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979164/ https://www.ncbi.nlm.nih.gov/pubmed/36873123 http://dx.doi.org/10.25122/jml-2021-0311 |
_version_ | 1784899669075165184 |
---|---|
author | Anindita, Brinna Sugihartono, Titong Miftahussurur, Muhammad Maimunah, Ummi Nusi, Iswan Abbas Setiawan, Poernomo Boedi Purbayu, Herry Kholili, Ulfa Widodo, Budi Thamrin, Husin Vidyani, Amie Rezkitha, Yudith Annisa Ayu Yamaoka, Yoshio |
author_facet | Anindita, Brinna Sugihartono, Titong Miftahussurur, Muhammad Maimunah, Ummi Nusi, Iswan Abbas Setiawan, Poernomo Boedi Purbayu, Herry Kholili, Ulfa Widodo, Budi Thamrin, Husin Vidyani, Amie Rezkitha, Yudith Annisa Ayu Yamaoka, Yoshio |
author_sort | Anindita, Brinna |
collection | PubMed |
description | Inflammatory bowel disease (IBD) with a poor prognosis may be due to persistent colitis. According to the latest guidelines, monitoring has become a part of the treatment process for colitis. Adequate monitoring of the patient's condition is necessary to determine the course of the disease to prevent the worsening of the condition and suppress the subclinical inflammatory process. This analytical study with a cross-sectional design was conducted to evaluate the activity of colitis using the results of C-reactive protein (CRP) and fecal calprotectin (FC) assays. FC levels were analyzed by ELISA, while CRP levels were analyzed using Siemens Flex particle-enhanced turbidimetric immunoassay. In 30 subjects with endoscopy and biopsy of colitis, 16 men and 14 women had a median age of 52.5 (18–70) years. The median FC value increased by 67 (7.3–722 g/g) and was positive (≥50 g/g) in 20 subjects (66.7%), and the mean CRP value was 13.64 mg/L, positive (10–15 mg/L) in 13 subjects (43.33%), and negative (<10 mg/L) in 17 subjects (56.67%). This study demonstrated that FC had a significant relationship with CRP (r=0.57; p<0.001) in patients with colitis. Assessing the levels of FC and CRP among patients with colitis can be useful to assess the worsening of symptoms early and reduce mortality and morbidity. |
format | Online Article Text |
id | pubmed-9979164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Carol Davila University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-99791642023-03-03 High levels of fecal calprotectin and C-reactive protein in patients with colitis Anindita, Brinna Sugihartono, Titong Miftahussurur, Muhammad Maimunah, Ummi Nusi, Iswan Abbas Setiawan, Poernomo Boedi Purbayu, Herry Kholili, Ulfa Widodo, Budi Thamrin, Husin Vidyani, Amie Rezkitha, Yudith Annisa Ayu Yamaoka, Yoshio J Med Life Original Article Inflammatory bowel disease (IBD) with a poor prognosis may be due to persistent colitis. According to the latest guidelines, monitoring has become a part of the treatment process for colitis. Adequate monitoring of the patient's condition is necessary to determine the course of the disease to prevent the worsening of the condition and suppress the subclinical inflammatory process. This analytical study with a cross-sectional design was conducted to evaluate the activity of colitis using the results of C-reactive protein (CRP) and fecal calprotectin (FC) assays. FC levels were analyzed by ELISA, while CRP levels were analyzed using Siemens Flex particle-enhanced turbidimetric immunoassay. In 30 subjects with endoscopy and biopsy of colitis, 16 men and 14 women had a median age of 52.5 (18–70) years. The median FC value increased by 67 (7.3–722 g/g) and was positive (≥50 g/g) in 20 subjects (66.7%), and the mean CRP value was 13.64 mg/L, positive (10–15 mg/L) in 13 subjects (43.33%), and negative (<10 mg/L) in 17 subjects (56.67%). This study demonstrated that FC had a significant relationship with CRP (r=0.57; p<0.001) in patients with colitis. Assessing the levels of FC and CRP among patients with colitis can be useful to assess the worsening of symptoms early and reduce mortality and morbidity. Carol Davila University Press 2023-01 /pmc/articles/PMC9979164/ /pubmed/36873123 http://dx.doi.org/10.25122/jml-2021-0311 Text en ©2022 JOURNAL of MEDICINE and LIFE https://creativecommons.org/licenses/by/3.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Original Article Anindita, Brinna Sugihartono, Titong Miftahussurur, Muhammad Maimunah, Ummi Nusi, Iswan Abbas Setiawan, Poernomo Boedi Purbayu, Herry Kholili, Ulfa Widodo, Budi Thamrin, Husin Vidyani, Amie Rezkitha, Yudith Annisa Ayu Yamaoka, Yoshio High levels of fecal calprotectin and C-reactive protein in patients with colitis |
title | High levels of fecal calprotectin and C-reactive protein in patients with colitis |
title_full | High levels of fecal calprotectin and C-reactive protein in patients with colitis |
title_fullStr | High levels of fecal calprotectin and C-reactive protein in patients with colitis |
title_full_unstemmed | High levels of fecal calprotectin and C-reactive protein in patients with colitis |
title_short | High levels of fecal calprotectin and C-reactive protein in patients with colitis |
title_sort | high levels of fecal calprotectin and c-reactive protein in patients with colitis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979164/ https://www.ncbi.nlm.nih.gov/pubmed/36873123 http://dx.doi.org/10.25122/jml-2021-0311 |
work_keys_str_mv | AT aninditabrinna highlevelsoffecalcalprotectinandcreactiveproteininpatientswithcolitis AT sugihartonotitong highlevelsoffecalcalprotectinandcreactiveproteininpatientswithcolitis AT miftahussururmuhammad highlevelsoffecalcalprotectinandcreactiveproteininpatientswithcolitis AT maimunahummi highlevelsoffecalcalprotectinandcreactiveproteininpatientswithcolitis AT nusiiswanabbas highlevelsoffecalcalprotectinandcreactiveproteininpatientswithcolitis AT setiawanpoernomoboedi highlevelsoffecalcalprotectinandcreactiveproteininpatientswithcolitis AT purbayuherry highlevelsoffecalcalprotectinandcreactiveproteininpatientswithcolitis AT kholiliulfa highlevelsoffecalcalprotectinandcreactiveproteininpatientswithcolitis AT widodobudi highlevelsoffecalcalprotectinandcreactiveproteininpatientswithcolitis AT thamrinhusin highlevelsoffecalcalprotectinandcreactiveproteininpatientswithcolitis AT vidyaniamie highlevelsoffecalcalprotectinandcreactiveproteininpatientswithcolitis AT rezkithayudithannisaayu highlevelsoffecalcalprotectinandcreactiveproteininpatientswithcolitis AT yamaokayoshio highlevelsoffecalcalprotectinandcreactiveproteininpatientswithcolitis |